With the American Society of Clinical Oncology's annual meeting happening this week in Atlanta, a new generation of cancer treatments is attracting attention. (BusinessWeek's Catherine Arnst reports on the progress here.) Meanwhile, a new Silicon Valley startup is developing treatments for cancer associated with defective DNA repair mechanisms. The DNA Repair Company was founded two years ago to create technology based on a patent held by Harvard University's Dana Farber Cancer Institute and Oregon Health & Science University, both of which have discovered various genes linked to cancer and have studied the body's response to damaged DNA that can lead to cancer. The DNA Repair Co.'s treatments aim to alleviate damage to the body's mechanisms for repairing DNA. Alan D'Andrea of the Dana Farber Cancer Institute is on the company's board, as is William A. Haseltine, former chairman and CEO at Human Genome Sciences, Inc. In April, the startup raised $2 million from VC firm Mohr Davidow Ventures in its first round of financing. MDV partner Michael Goldberg is serving as CEO.
Before it's here, it's on the Bloomberg Terminal. LEARN MORE